HealthCare and Hospital Management

Dr. Farid Menaa is an inter- and multi-disciplinary professional with worldwide reputation. He has three international post-doctoral terms in Oncology, Dermatology, and Hematology; MBA Entrepreneurship and MD candidate. During his ongoing career, he has mainly contributed to the identification and functions of new human disease-causing genes and variants, formulated natural products for anti-aging and developed innovative theranostic strategies against cancers, cardiovascular diseases, diabetes, obesity and infectious diseases. He has more than 10 years’ experiences either in the academic, hospitals or industrial sectors. As Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. he actively participated in the development of the disruptive “Carbon-Fluorine Spectroscopy”. Dr. Menaa collaborates with various organizations worldwide. He is a member of several prestigious medical and scientific organizations and editorial boards in the field of medicine, science, technology and business, including in the nano-segment. He has authored more than 100 articles including research and review articles, books, book chapters, textbooks, proceedings, and has participated to over 200 scientific international events including as co-organizer, keynote speaker, chairman. Dr. Menaa’s worldwide collaborations, holistic point of view and strong expertise in various fields led him to prevent, implement early diagnosis, and develop efficient and safer therapy.

Dr. Farid Menaa’s research interest includes Preventive Medicine, Personalized Medicine, Translational Medicine, Integrative Medicine, Green Medicine, Nanomedicine, Biotechnology, and Nanotechnology.

Prof. Andrey Nikolaevych Belousov graduate from Kharkov Medical Institute in 1988. Doctor of Medicine degree on speciality - An¬esthesiology and Intensive Care since 2004. The title dissertation: “Extracorporal hemocorrection using magnet-controlled sorbent in intensive therapy of intoxication syndromes in patients with hepatopancreatoduodenales dis¬eases”. Author a new medecine products – nanotechnology preparations based on magnetite nanoparticles (Fe3O4) of the size 6-12 nm (www.nanolab.com.ua): the peroral form - Micromage-B (the biologically active additive officially registration in Ukraine); Magnet-controlled sorbent brand of MCS-B for extracorporal detoxication of biological liquids (officially registration in Ukraine and was allowed for medical practice); NanoBiocorrector for intravenous application – ICNB (intracorporal nanosorbent).

Nanomedicine, Intensive Care, An¬esthesiology, Transfusiology.

Monika H. Seltenhammer completed her VMD. and Ph.D. from VMU in Austria and postdoctoral studies from Veterinary University of Vienna, Max Perutz Laboratories and Medical University of Vienna in Austria, where her core area of scientific work mainly consisted in cancer research (melanoma) and pathology, but also immunology, neurology and virology. She has received several honor and awards. She is a leading member of the scientific staff from the Department of Forensic Medicine of the Medical University Vienna

Her research interest includes cancer research pathology, neurology and virology

Ayman M Noreddin received his PhD in Pharmaceutical Sciences from the University of the Pacific, California and received research training as a visiting scholar at the Department of Medicine, Stanford University. He had Post-doctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, University of Manitoba followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). His research interest includes Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies. He has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.

• Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy • Clinical simulation and Monte Carlo analysis • Bacterial resistance in biofilm studies • Minority health care studies Research Focus • Anti-infective translational research in relation to antimicrobial resistance: Our goal is to improve patient care by maximizing clinical outcomes and preventing the development of bacterial resistance . • Anti-Cancer translational research in relation to 3D modeling and epigenetic studies: Our goal is to optimize cancer chemotherapy and overcome/reverse the development of resistance.